Growth & profitability
- Revenue has grown 99.2% per year over the past 4 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
SCNI Financials Scinai Immunotherapeutics Ltd.
5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1M | -$8M | -202.3% | -575.3% | -$6M | — | $2M |
| 2024 | $658000 | $5M | -88.1% | -1312.8% | -$6M | — | $2M |
| 2023 | — | -$7M | — | — | -$10M | — | $5M |
| 2022 | — | -$6M | — | — | -$8M | — | $14M |
| 2021 | — | -$8M | — | — | -$8M | — | $17M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Jun '23 | — | -$4M | — | — | -$3M | — | $8M |
| Mar '23 | — | -$4M | — | — | -$3M | — | $11M |
| Jun '22 | — | -$3M | — | — | -$4M | — | $11M |
| Mar '22 | — | -$2M | — | — | -$2M | — | $15M |
Valuation over time
How the market has priced SCNI against its own fundamentals since 2023-09 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 6465.2× (Dec '24) to 1888.9× (Nov '25).
- The price-to-sales ratio has fallen from 47123.1× (Dec '24) to 1859.3× (Jun '26).
P/E
P/S
Frequently asked questions
Is SCNI growing its revenue and profit?
Over the past 4 years, Scinai Immunotherapeutics Ltd.'s revenue has grown 99.2% per year. These are computed facts, not advice.
How much debt does SCNI have?
As of FY2025, Scinai Immunotherapeutics Ltd. reported — of total debt against $2M of cash.
What is SCNI's profit margin?
In FY2025, gross margin was -202.3%, operating margin -575.3%, and net margin -633.6%.
What is SCNI's P/E ratio?
As of Jun '26, Scinai Immunotherapeutics Ltd. traded at a price-to-earnings ratio of about 1888.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.